Drugs / autologous NK cell
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05909098 | Jul 2023 → Dec 2026 expected | B-cell non-Hodgkin lymphoma | Xiangyang No.1 People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04558931 | Jun 2021 → Dec 2027 expected | plasma cell myeloma | Karolinska Institutet | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07375563 | Nov 2025 → Dec 2026 expected | ganglioneuroblastoma, neuroblastoma | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous NK cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07375563 ↗ |
| Known as | CellProtect | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04558931 ↗ |
| Modality | Cell therapy | “In vitro expanded and activated autologous NK cells” NCT04558931 ↗ |
| Route | Intravenous | “CellProtect will be given IV infusion” NCT04558931 ↗ |